docetaxel chemotherapy
Showing 1 - 25 of >10,000
Triple Negative Breast Cancer, Anthracycline-refractory TNBC Trial in Houston (Docetaxel, Pembrolizumab, IL-12 gene therapy)
Suspended
- Triple Negative Breast Cancer
- Anthracycline-refractory TNBC
- Docetaxel
- +2 more
-
Houston, TexasHouston Methodist Cancer Center
Mar 28, 2022
Advanced NSCLC Trial (Trilaciclib+Envafolimab+Docetaxel, Envafolimab+Docetaxel, Docetaxel)
Not yet recruiting
- Advanced Non-Small Cell Lung Cancer
- (no location specified)
Jun 16, 2023
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,
Not yet recruiting
- HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
- PERT-IJS plus trastuzumab, carboplatin and docetaxel
- Perjeta plus trastuzumab, carboplatin and docetaxel
- (no location specified)
Sep 21, 2023
Prostate Cancer Trial in Madison (Docetaxel, Degarelix, Bicalutamide)
Completed
- Prostate Cancer
- Docetaxel
- +3 more
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Sep 12, 2022
Breast Cancer, Chemo Effect Trial (Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel, Epirubicin, Cyclophosphamide,
Not yet recruiting
- Breast Cancer
- Chemotherapy Effect
- Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel
- Epirubicin, Cyclophosphamide, Docetaxel
- (no location specified)
Jun 21, 2023
Locally Advanced Gastric Adenocarcinoma, Chemo Effect Trial in Hanzhou (Docetaxel, Tegafur-Gimeracil-Oteracil)
Recruiting
- Locally Advanced Gastric Adenocarcinoma
- Chemotherapy Effect
-
Hanzhou, Zhejiang, ChinaGastrointestinal Department of Second Affiliated Hospital of Zhe
Apr 2, 2023
Gastric Cancer, Stomach Cancer, GastroEsophageal Cancer Trial in Kyiv (Docetaxel, Oxaliplatin, Leucovorin)
Recruiting
- Gastric Cancer
- +10 more
- Docetaxel
- +3 more
-
Kyiv, UkraineNational Cancer Institute
Aug 31, 2023
Breast Cancer Trial (Utidelone Injection in combination with AC, Docetaxel Injection in combination with AC)
Not yet recruiting
- Breast Cancer
- Utidelone Injection in combination with AC
- Docetaxel Injection in combination with AC
- (no location specified)
Jan 10, 2023
Gastric Cancer, Adjuvant Chemo, XO Trial in Seoul (Docetaxel and capecitabine and oxaliplatin, capecitabine and oxaliplatin)
Recruiting
- Gastric Cancer, Adjuvant Chemotherapy, XO
- Docetaxel and capecitabine and oxaliplatin
- capecitabine and oxaliplatin
-
Seoul, Korea, Republic ofAsan Medical Center
Dec 30, 2022
NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- MK-2870
- +2 more
- (no location specified)
Oct 3, 2023
Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)
Recruiting
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Docetaxel
- +3 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023
Locally Advanced or Metastatic NSCLC Trial (Utidelone Injection, Docetaxel Injection)
Not yet recruiting
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Utidelone Injection
- Docetaxel Injection
- (no location specified)
Dec 30, 2022
Nasopharyngeal Carcinoma Trial in Guangzhou (Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel),
Not yet recruiting
- Nasopharyngeal Carcinoma
- Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
- +3 more
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Sep 17, 2022
Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemo Effect Trial in Nanjing (Docetaxel, Rezvilutamide)
Recruiting
- Metastatic Prostate Cancer
- +2 more
-
Nanjing, Jiangsu, ChinaUrology dpt, First Affiliated Hospital of Nanjing Medical Univer
Aug 2, 2023
Non-small-cell Lung Cancer Trial in China (TQB2450 +Anlotinib+Docetaxel, TQB2450 +Androtinib Placebo+Docetaxel)
Recruiting
- Non-small-cell Lung Cancer
- TQB2450 +Anlotinib+Docetaxel
- TQB2450 +Androtinib Placebo+Docetaxel
-
Huizhou, Guangdong, China
- +4 more
Nov 15, 2023
Hyperthermic Intraperitoneal Chemo Trial in Guangzhou (Docetaxel)
Recruiting
- Hyperthermic Intraperitoneal Chemotherapy
-
Guangzhou, Other (Non U.s.), ChinaSun Yat-sen Memorial Hospital
Jun 6, 2022
Oral Squamous Cell Carcinoma Trial in Wuhan (Camrelizumab plus TP, TP)
Not yet recruiting
- Oral Squamous Cell Carcinoma
- Camrelizumab plus TP
- TP
-
Wuhan, Hubei, ChinaHospital of Stomatology, Wuhan University
Mar 22, 2023
Breast Tumors Trial in Shanghai (Epirubicin, Docetaxel, cyclophosphamide)
Completed
- Breast Neoplasms
- Epirubicin
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital
Oct 26, 2022
Non-muscle-invasive Bladder Cancer Trial in Zagreb (Gemcitabine 1000 mg, Docetaxel 37.5g)
Active, not recruiting
- Non-muscle-invasive Bladder Cancer
- Gemcitabine 1000 mg, Docetaxel 37.5g
-
Zagreb, CroatiaUniversity Hospital Centre Zagreb
Jan 20, 2023
Breast Cancer, Chemo Effect Trial (Nab paclitaxel, Docetaxel)
Not yet recruiting
- Breast Cancer
- Chemotherapy Effect
- Nab paclitaxel
- Docetaxel
- (no location specified)
Feb 11, 2022
Breast Tumors Trial in Guangzhou (Trilaciclib, Epirubicin, Cyclophosphamide)
Not yet recruiting
- Breast Neoplasms
- Trilaciclib
- +7 more
-
Guangzhou, Gangdong, ChinaSun-yat sen university cancer center
Jul 30, 2023
Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With
Enrolling by invitation
- Gastric Cancer
- Gastrectomy
- +3 more
-
Shanghai, Shanghai, ChinaZhongshan hospital
May 1, 2022
NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Tumor treating fields(EFE-P100)
- Docetaxel injection
-
Shanghai, ChinaShanghai Pulmonary Hospital
Dec 21, 2022
Breast Cancer Trial in Rouen (pharmacokinetics blood sample assessment)
Not yet recruiting
- Breast Cancer
- pharmacokinetics blood sample assessment
-
Rouen, FranceCentre Henri Becquerel
May 11, 2023
Metastatic Castration Resistant Prostate Cancer Trial in India (Enzalutamide, Androgen deprivation therapy (ADT))
Active, not recruiting
- Metastatic Castration Resistant Prostate Cancer
- Enzalutamide
- Androgen deprivation therapy (ADT)
-
Ahmedabad, India
- +7 more
Jan 21, 2023